IN THE CLAIMS:

The following is a complete listing of the claims:

101. (Currently amended) A method for treating cancer which comprises administering to a mammal a therapeutically-effective combination of chemotherapeutic agents comprising (1) at least one anti-metabolite selected from capecitabine and/or 5-fluorouracil, and (2) Compound (1), having the formula,



, or a pharmaceutically-acceptable salt, hydrate, solvate, or geometric, optical, or stereoisomer of Compound (1), wherein the cancer is selected from one or more of cancer of the bladder, breast, colon, kidney, liver, lung, ovaries, prostate, testes, genitourinary tract, lymphatic system, rectum, larynx, pancreas, esophagus, stomach, gall bladder, cervix, thyroid, and skin, or is a hematopoietic tumor of lymphoid and/or myeloid lineage, tumor of the central and/or peripheral nervous system, tumor of mesenchymal origin, melanoma, xenoderma pigmentosum, keratoactanthoma, seminoma, thyroid follicular cancer, and/or teratocarcinoma.

102. (Previously presented) The method according to claim 101, wherein the anti-metabolite is capecitabine administered following the administration of Compound 1.

103. (Previously presented) The method according to claim 101, wherein the anti-metabolite is capecitabine administered before the administration of Compound 1.

104. (Previously presented) The method according to claim 101, wherein the anti-metabolite is capecitabine administered substantially simultaneously with the administration of Compound 1.

105. (Previously presented). The method according to claim 101, comprising the treatment of cancerous solid tumors.

106. (Previously presented) The method according to claim 101, comprising the treatment of refractory tumors.

107. (Previously presented) The method according to claim 101, wherein the cancer is metastatic breast cancer.

108. (Previously presented) The method according to claim 101, wherein the cancer is lung cancer.

109. (Previously presented) The method according to claim 101, wherein the cancer is prostate cancer.

110. (Previously presented) The method according to claim 101, wherein the cancer is pancreatic cancer.

111 (Currently amended). A pharmaceutical product for administering a combination of anti-proliferative agents to a mammal, the product comprising in a first package an anti-metabolite selected from capecitabine and/or 5-fluorouracil, and in a second package, Compound (1), which is,



, or a pharmaceutically-acceptable salt, hydrate, solvate, or geometric, optical, or stereoisomer of Compound (1).

112 (Previously presented). The product according to Claim 111 wherein the anti-metabolite is capecitabine.

113 (New). The method according to claim 101, wherein the cancer is resistant, refractory, or sensitive to taxane treatment.

114 (New). The method according to claim 107, wherein the cancer is resistant, refractory or sensitive to taxane treatment.

115 (New). The method according to claim 101, wherein the Compound (1) is administered orally.

116 (New). The method according to claim 107, wherein the Compound (1) is administered orally.

117 (New). A method of treating cancer in a mammal selected from metastatic breast cancer, lung cancer, pancreatic cancer, ovarian cancer, prostate cancer, colon cancer, and/or small cell lung cancer, comprising administering to the mammal a therapeutically-effective combination of (1) a dosage unit of capecitabine and (2) a dosage unit of Compound (1), having the formula,



or a pharmaceutically-acceptable salt, hydrate, solvate, or geometric, optical, or stereoisomer of Compound (1), wherein the administration will provide a greater anti-cancer effect than the effect obtainable with either the dosage unit of capecitabine or the dosage unit of Compound (1) alone.

118 (New). The method of claim 117 wherein the cancer is metastatic breast cancer refractory to taxane treatment.

119 (New). The method of claim 117 wherein the cancer is metastatic breast cancer resistant to taxane treatment.

120 (New). The method of claim 117 wherein the cancer is metastatic breast cancer sensitive to taxane treatment.

121. (New) The method according to claim 117, wherein the capecitabine is administered following the administration of Compound 1.

122. (New) The method according to claim 117, wherein the capecitabine is administered before the administration of Compound 1.

123. (New) The method according to claim 117, wherein the capecitabine is administered substantially simultaneously with the administration of Compound 1.

124. (New) The method according to claim 117, wherein the capecitabine is administered orally and the Compound 1 is administered parenterally.

125. (New) The method according to claim 117, wherein the capecitabine is administered orally and the Compound 1 is administered orally.

126 (New). A method of treating cancer in a mammal selected from metastatic breast cancer, lung cancer, pancreatic cancer, ovarian cancer, prostate cancer, colon cancer, and/or small cell lung cancer, comprising administering to the mammal a synergistically-effective combination of (1) at least one anti-metabolite selected from capecitabine and/or 5-fluorouracil, and (2) Compound (1), having the formula,



or a pharmaceutically-acceptable salt, hydrate, solvate, or geometric, optical, or stereoisomer of Compound (1).

127 (New). The method of claim 126, wherein the cancer is metastatic breast cancer and the anti-metabolite is capecitabine.

128 (New). The method of claim 126 wherein the cancer is refractory to taxane treatment.

129 (New). The method of claim 126 wherein the cancer is resistant to taxane treatment.

130 (New). The method of claim 126 wherein the cancer is sensitive to taxane treatment.